Alpine Immune Sciences is a biotechnology business based in the US. Alpine Immune Sciences shares (ALPN) are listed on the NASDAQ and all prices are listed in US Dollars. Alpine Immune Sciences employs 142 staff and has a trailing 12-month revenue of around $56.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.60 |
|---|---|
| 52-week range | $7.50 - $64.97 |
| 50-day moving average | $53.15 |
| 200-day moving average | $26.84 |
| Wall St. target price | $62.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.64 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.6 from 2024-07-24
| 1 week (2024-07-19) | 1.33% |
|---|---|
| 1 month (2024-06-26) | 0.66% |
| 3 months (2024-04-26) | -88.23% |
| 6 months (2024-01-26) | -69.75% |
| 1 year (2023-07-26) | -35.59% |
|---|---|
| 2 years (2022-07-26) | -5.71% |
| 3 years (2021-07-26) | 8.44 |
| 5 years (2019-07-26) | 62.74% |
| Revenue TTM | $56.5 million |
|---|---|
| Gross profit TTM | $-40,179,000 |
| Return on assets TTM | -10.1% |
| Return on equity TTM | -14.67% |
| Profit margin | -65.17% |
| Book value | $5.08 |
| Market Capitalization | $4.5 billion |
TTM: trailing 12 months
We're not expecting Alpine Immune Sciences to pay a dividend over the next 12 months.
Alpine Immune Sciences's shares were split on a 1:4 basis on 24 July 2017. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alpine Immune Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Alpine Immune Sciences shares which in turn could have impacted Alpine Immune Sciences's share price.
Over the last 12 months, Alpine Immune Sciences's shares have ranged in value from as little as $7.5 up to $64.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alpine Immune Sciences's is 0.969. This would suggest that Alpine Immune Sciences's shares are less volatile than average (for this exchange).
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.